RC110 is viable in AML which is the indication that Race took to Phase 2. What it isn't is ideal for is use in combination with doxorubicin (or any other anthracycline) as a cardioprotective anticancer agent.
RC220 was developed by Race and it wasn't known when the Phase 2 AML trials were started.
RC220 is not being advanced as a quicker pathway to market for bisantrene (RC110 would have been much faster ), but as the opportunity with the greatest potential returns for RAC shareholders. The opportunity for RC220 is so much larger than RC110 that we felt it was worth the cost in time to convert over all our clinical programs to using it. We could have kept on developing RC110 and ignored RC220, but that would have meant giving up most of the potential return from bisantrene. When you make important discoveries in the lab or clinic you have to make changes in strategic direction.
RC110 is viable in AML which is the indication that Race took to...
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.74 |
Change
-0.045(2.53%) |
Mkt cap ! $293.1M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.70 | $187.9K | 107.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 187 | $1.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 1000 | 1 |
View Market Depth
| Last trade - 11.10am 02/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |